in this multicentre study a controlled-release formulation of levodopa and the decarboxylase inhibitor benserazide ( madopar cr ) was evaluated in patients with parkinson 's disease exhibiting dose-related fluctuations in motor performance in response to conventional levodopa preparations .
C0030567
parkinson 's disease
C0023570
levodopa